参考文献/References:
[1].Agarwal S,Agrawal D. Kawasaki disease:etiopathogenesis and novel treatment strategies[J]. Expert Rev Clin Immunol,2016,13(3):247-258.
[2].Yoshida M,Oana S,Masuda H,et al. Recurrence of fever after initial intravenous immunoglobulin treatment in children with Kawasaki disease[J]. Clin Pediatr,2017,57(2):189-192.
[3].Okuma Y,Suda K,Nakaoka H,et al. Serum tenascin-C as a novel predictor for risk of coronary artery lesion and resistance to intravenous immunoglobulin in Kawasaki disease—a multicenter retrospective study[J]. Circ J,2016,80(11):2376-2381.
[4].Kim MK,Song MS,Kim GB. Factors predicting resistance to intravenous immunoglobulin treatment and coronary artery lesion in patients with Kawasaki disease:analysis of the Korean nationwide multicenter survey from 2012 to 2014[J]. Korean Circ J,2018,48(1):71-79.
[5].Mingardi J,Musazzi L,de Petro G,et al. miRNA editing:new insights into the fast control of gene expression in health an d di sease[J]. Mol Neurobiol,2018,55(3):1-11.
[6].Icli B,Dorbala P,Feinberg M. An emerging role for the miR-26 family in cardiovascular disease[J]. Trends Cardiovasc Med,2014,24(6):241-248.
[7].Pinchi E,Frati P,Aromatario M,et al. miR-1,miR-499 and miR-208 are sensitive markers to diagnose sudden death due to early acute myocardial infarction[J]. J Cell Mol Med ,2019,23(9):6005-6016.
[8].Ogawa S,Ayusawa M,Fukazawa R,et al. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013) - Digest Version[J]. Circ J, 2014,78(10):2521-2562.
[9].Research Committee of the Japanese Society of Pediatric Cardiology,Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki Disease. Guidelines for medical treatment of acute Kawasaki disease:report of the research committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery(2012 revised version)[J]. Pediatr Int,2014,56(2):135-158.
[10].Levine GN,Bates ER,Bittl JA,et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease[J]. Circulation,2016,134(10):123-155.
[11].Chen K,Curtis N,Dahdah, N,et al. Kawasaki disease and cardiovascular risk:a comprehensive review of subclinical vascular changes in the longer term[J]. Acta Paediatr,2016,105(7):752-761.
[12].Okubo Y,Nochioka K,Sakakibara H,et al. National survey of pediatric hospitalizations due to Kawasaki disease and coronary artery aneurysms in the USA[J]. Clin Rheumatol,2016,36(2):413-419.
[13].Ammirati E,Burns J,Moreo A,et al. Extreme giant aneurysms of three coronary arteries causing heart failure as late sequelae of Kawasaki disease[J]. Eur Heart J,2017,38(10):759-760.
[14].Lauschke V,Vorrink S,Moro S,et al. Massive rearrangements of cellular miRNA signatures are key drivers of hepatocyte dedifferentiation[J]. Hepatology,2016,64(5):1743-1756.
[15].Su T,Shao X,Zhang X,et al. Initial concentrations of miR-1 microRNA precursor and high-sensitivity troponin in the diagnosis of non- ST m yocardial infarction among patients with and those without chronic kidney disease[J]. Cardiorenal Med,2019,9(5):274-283.
[16].Lu S,Lu Y. MiR-26a inhibits myocardial cell apoptosis in rats with acute myocardial infarction through GSK-3β pathway[J]. Eur Rev Med Pharmacol Sci,2020,24(5):2659-2666.
[17].Li S,Ma X,Ji J,et al. miR-1 association with cell proliferation inhibition and apoptosis in vestibular schwannoma by targeting VEGFA[J]. Genet Mol Res,2016,15(4):1-8.
[18].Lu J,Zhao F,Peng Z,et al. EZH2 promotes angiogenesis through inhibition of miR-1/endothelin-1 axis in nasopharyngeal carcinoma[J]. Oncotarget,2014,5(22):11319-11332.
[19].Yan J,Wang H,Gao LX. Diagnostic value of serum miR-1 in patients with acute Kawasaki disease[J]. Clin Lab,2019,65(7). DOI:10.7754/Clin.Lab.2019.190339.
[20].Zhou Y,Wang S,Zhao J,et al. Correlations of complication with coronary arterial lesion with VEGF,PLT,D-dimer and inflammatory factor in child patients with Kawasaki disease[J]. Eur Rev Med Pharmacol Sci,2018,22(16):5121-5126.
[21].Chen C,Chang J,Ho Y,et al. MiR-26 down-regulates TNF-α/NF-κB signalling and IL-6 expression by silencing HMGA1 and MALT1[J]. Nucleic Acids Res,2016,44(8):3772-3787.
[22].Tian J,An X,Niu L. Correlation between NF-κB signal pathway-mediated caspase-4 activation and Kawasaki disease[J]. Exp Ther Med,2017,13(6):3333-3336.
相似文献/References:
[1]杨再英,王钰.川崎病后无创检查评估血管内皮功能的研究进展[J].心血管病学进展,2019,(6):939.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.025]
YANG Zaiying,WANG Yu.Non-invasive Assessment of Vascular Endothelial Function after Kawasaki Disease[J].Advances in Cardiovascular Diseases,2019,(5):939.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.025]
[2]石树文 田雯.肠道微生物群与儿童川崎病[J].心血管病学进展,2020,(6):608.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.012]
SHI ShuwenTIAN Wen. Intestinal microbiota and children Kawasaki disease[J].Advances in Cardiovascular Diseases,2020,(5):608.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.012]
[3]王琼琼,赵胜.血小板活化在川崎病中的研究进展[J].心血管病学进展,2021,(6):552.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.000]
WANG QiongqiongZHAO Sheng.Platelet Activation in the Pathogenesis of Kawasaki Disease[J].Advances in Cardiovascular Diseases,2021,(5):552.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.000]
[4]李红霞 朱凯 刘雯 王慧 杨涛毅.0～5岁川崎病儿童静脉注射免疫球蛋白耐药的相关因素分析及预测模型构建[J].心血管病学进展,2023,(3):283.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.020]
LI HongxiaZHU KaiLIU WenWANG HuiYANG Taoyi?/html>.Analysis of Related Factors and Prediction Model?f Intravenous Immunoglobulin Resistance in Children with Kawasaki Disease Aged 0 5 Years[J].Advances in Cardiovascular Diseases,2023,(5):283.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.020]
[5]王慧 张燕平 王志强 陈桂华 谢江.基于孟德尔随机化探索肠道菌群与儿童川崎病之间的因果关系[J].心血管病学进展,2023,(6):572.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.020]
WANG HuiZHANG Yanping,WANG Zhiqiang,CHEN Guihua,et al.To Explore the Causal Relationship Between Gut Microbiota and Kawasaki Disease in Children Based on Mendelian Randomization[J].Advances in Cardiovascular Diseases,2023,(5):572.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.020]